Cabaletta Bio is focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Successful clinical trials in patients are required to gain regulatory approval for new medications to advance patient care and may be required to support any approved products. Information about Cabaletta Bio clinical trials is listed below.
DesCAARTes™ Clinical Trial+
A Phase I Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Mucosal Pemphigus Vulgaris, Sponsored by Cabaletta Bio, Inc.
Cabaletta Bio is planning to open this Phase 1 clinical trial in 2020. Please check again at a future date for additional information.